Protein PEGylation for cancer therapy: bench to bedside

Promising role for Gc-MAF in cancer immunotherapy: from bench to bedside

Immunotherapy has been used for years in many types of cancer therapy. Recently, cancer immunotherapy has focused on mechanisms which can enhance the development of cell-mediated immunity. Anticancer medications are administered to inhibit immunosuppressive factors such as nagalase enzyme, which is produced by neoplastic cells and destroys macrophage activating factor (Gc-MAF). Anti-neoplastics...

KCNE2 and gastric cancer: bench to bedside

Gastric cancer (GC) is one of the most common cancers worldwide. Among GC patients the mortality rate remains high-most are diagnosed at advanced disease stages due to the lack of symptoms in early disease. Prominent risk factors include age, male sex, smoking, radiation, H. pylori colonization, and a positive family history. Depending on tumor staging, treatment consists of neoadjuvant, adjuva...

Nanoparticle PEGylation for Cancer Therapy

Currently, there are more than 35 US FDA-approved NPs utilizing PEG in their biomedical applications. PEGylation, which is the addition of PEG to the NP formulation, provides immunity from the hostile biological environment. The ‘stealth’ property, further confers on the PEG-NP formulation benefits that are not normally provided by other polymers. This mini-review briefly describes the mechanis...

Rational therapy from bench to bedside for a rare epilepsy.

Hyperbaric oxygen therapy for traumatic brain injury: bench-to-bedside

Traumatic brain injury (TBI) is a serious public health problem in the United States. Survivors of TBI are often left with significant cognitive, behavioral, and communicative disabilities. So far there is no effective treatment/intervention in the daily clinical practice for TBI patients. The protective effects of hyperbaric oxygen therapy (HBOT) have been proved in stroke; however, its effici...